Avinger, Inc. (NASDAQ:AVGR) Short Interest Down 29.1% in January

Avinger, Inc. (NASDAQ:AVGR) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 166,300 shares, a decline of 29.1% from the December 31st total of 234,700 shares. Based on an average daily trading volume, of 2,170,000 shares, the short-interest ratio is presently 0.1 days. Approximately 6.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Avinger in a research note on Wednesday. They set a “hold” rating for the company.

Avinger Trading Down 4.2 %

Shares of NASDAQ:AVGR traded down $0.03 during trading on Friday, hitting $0.58. 306,657 shares of the company were exchanged, compared to its average volume of 786,917. The stock has a market cap of $1.90 million, a price-to-earnings ratio of -0.05 and a beta of 1.15. Avinger has a fifty-two week low of $0.39 and a fifty-two week high of $5.45. The firm has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.95.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings results on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.21. Avinger had a negative net margin of 261.06% and a negative return on equity of 5,527.11%. The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.60 million. During the same period in the prior year, the firm posted ($2.92) earnings per share. As a group, research analysts predict that Avinger will post -4.69 EPS for the current year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.